The CHRCDA Program in the Department of Pediatrics at Duke University Medical Center is intended to foster the maturation of pediatric junior faculty into independent physician-scientists who are skilled in cutting-edge methods of laboratory research and who pursue long-term academic careers investigating important issues related to childhood diseases. This Program is based on a pool of outstanding candidates, a strong curriculum of didactic courses, experienced mentors who perform state-of-the-art laboratory research, and an excellent research environment. The Principal Investigator/Program Director and the Training Director will receive assistance from an Internal Advisory Board and an External Advisory Board in selecting scholars, reviewing the progress of scholars, and ensuring the optimal operation of the program. Four scholars will be supported each year and will be drawn from junior faculty in the Department of Pediatrics, with particular emphasis on recruitment of women and underrepresented minorities. The Program Faculty will be drawn from four broadly defined areas of research excellence, namely Developmental Biology, Cell Biology and Cell Signaling, Infection and Immunity, and Genetics, Genomics, and Metabolomics. The Program Faculty will include mentors from the Department of Pediatrics and from other departments at Duke University Medical Center, in all cases characterized by a strong track record in research, funding, and mentoring. Didactic courses will complement the laboratory research experiences and will include a four-lecture course on writing and a five-lecture course on Responsible Conduct of Research. The scholars will have access to all of the shared research facilities at Duke University, including core facilities of the NCI-funded Comprehensive Cancer Center, the Duke Institute for Genome Sciences and Policy, the Duke Center for Human Genome Variation, the Duke Center for Human Disease Modeling, the Duke Human Vaccine Institute, and the Duke Translational Medicine Institute, among others.
There is a paramount need for pediatricians who are skilled in modern scientific methods and have the background to develop novel approaches to the diagnosis, treatment, and prevention of childhood diseases. The proposed career development program will foster the maturation of talented pediatric junior faculty into independent investigators who use cutting-edge methods of laboratory research and who pursue long-term academic careers investigating important issues related to childhood diseases.
|Salerno, Sara; Hornik, Christoph P; Cohen-Wolkowiez, Michael et al. (2017) Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants. Pediatr Infect Dis J 36:855-859|
|Mankouski, Anastasiya; Kantores, Crystal; Wong, Mathew J et al. (2017) Intermittent hypoxia during recovery from neonatal hyperoxic lung injury causes long-term impairment of alveolar development: A new rat model of BPD. Am J Physiol Lung Cell Mol Physiol 312:L208-L216|
|Smith, P Brian; Benjamin Jr, Daniel K; Reed, Ann M (2017) The Role of a Division of Quantitative Sciences Division in Enhancing Academic Productivity of a Department of Pediatrics. J Pediatr 180:4-5|
|Louie, Raymond J; Tan, Queenie K-G; Gilner, Jennifer B et al. (2017) Novel pathogenic variants in FOXP3 in fetuses with echogenic bowel and skin desquamation identified by ultrasound. Am J Med Genet A 173:1219-1225|
|Ku, Lawrence C; Zimmerman, Kanecia; Benjamin, Daniel K et al. (2017) Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit. Pediatr Cardiol 38:155-161|
|Parente, V; Clark, R H; Ku, L et al. (2017) Risk factors for group B streptococcal disease in neonates of mothers with negative antenatal testing. J Perinatol 37:157-161|
|Younge, Noelle; Goldstein, Ricki F; Bann, Carla M et al. (2017) Survival and Neurodevelopmental Outcomes among Periviable Infants. N Engl J Med 376:617-628|
|Ku, Lawrence C; Wu, Huali; Greenberg, Rachel G et al. (2016) Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine. Ther Drug Monit 38:728-737|
|Shashi, V; McConkie-Rosell, A; Schoch, K et al. (2016) Practical considerations in the clinical application of whole-exome sequencing. Clin Genet 89:173-81|
|Zimmerman, Kanecia O; Wu, Huali; Greenberg, Rachel et al. (2016) Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients. Ther Drug Monit 38:600-6|
Showing the most recent 10 out of 83 publications